Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baruch Brenner

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Oncotargets and Therapy|November 25, 2020
Clinical Characteristics and Prognosis of Gastric Cancer Patients with <i>BRCA 1/2</i> Germline Mutations: Report of Ten Cases and a Literature ReviewNaama Halpern, Albert Grinshpun, Ben Boursi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer PatientsBaruch Brenner, Ravit Geva, Megan Rothney, et al.
The American Journal of Surgical Pathology|March 25, 2008
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?Jinru Shia, Laura H Tang, Martin R Weiser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Targeted Oncology|January 22, 2018
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical ExperienceOfer Purim, Alexander Beny, Moshe Inbar, et al.
The Oncologist|September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
Cancer Research|February 6, 2021
Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular VesiclesNil Grunberg, Meirav Pevsner-Fischer, Tal Goshen-Lago, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Frontiers in Pharmacology|May 6, 2026
Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trialsNahida Sakis, Liat Sorski, Eden Asraf, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Oncotargets and Therapy|November 25, 2020
Clinical Characteristics and Prognosis of Gastric Cancer Patients with <i>BRCA 1/2</i> Germline Mutations: Report of Ten Cases and a Literature ReviewNaama Halpern, Albert Grinshpun, Ben Boursi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer PatientsBaruch Brenner, Ravit Geva, Megan Rothney, et al.
The American Journal of Surgical Pathology|March 25, 2008
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?Jinru Shia, Laura H Tang, Martin R Weiser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Targeted Oncology|January 22, 2018
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical ExperienceOfer Purim, Alexander Beny, Moshe Inbar, et al.
The Oncologist|September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
Cancer Research|February 6, 2021
Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular VesiclesNil Grunberg, Meirav Pevsner-Fischer, Tal Goshen-Lago, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Frontiers in Pharmacology|May 6, 2026
Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trialsNahida Sakis, Liat Sorski, Eden Asraf, et al.
Pageof 12